Mitsubishi Tanabe Pharma Corp. has divulged proteolysis targeting chimeras (PROTACs) comprising a cereblon E3 ubiquitin ligase (CRBN) binding moiety coupled to disease-associated protein targeting moiety through a linker reported to be useful for the treatment of cancer, inflammatory disorders, autoimmune disease, neurodegeneration and genetic disorders.